Clay Siegall: Dreaming of Corporate Expansion

Clay Siegall is the founder and the current chief executive officer of Seattle Genetics, one of the largest healthcare, pharmaceutical and tech companies in the state of Washington. The company is known for manufacturing Adcertis, a drug that is used for the treatment of Hodgkin lymphoma, a kind of lymph system cancer that can be fatal if not treated. Clay Siegall stated that he is now planning to expand outside Washington, and it is his ultimate dream for Seattle Genetics to be known all throughout the country, and for the company to be able to manufacture pharmaceutical drugs for international use.

Seattle Genetics was founded in the year 1988, and the reason why Clay Siegall established the company is that he wanted to develop a medical treatment for fatal diseases like cancer. At first, there is only a handful of employees who decided to work with him. Through the years, the number of employees rose, and today, more than a thousand people work for the pharmaceutical firm. Clay Siegall stated that the company’s success could be attributed to the hard-working employees who are contributing a lot for the sake of the business. He stated that with the expansion of Seattle Genetics, more people would be given jobs, and the chances of the medicine that they manufacture to reach more people go up.

The noble cause of Clay Siegall to treat fatal diseases transformed the company from a small startup to one of the most profitable businesses in the state of Washington. The creation of Adcertis is also purely accidental, as Clay Siegall and his team of scientists are working for another cure until they mixed up all of the materials and ended up treating Hodgkin lymphoma. The FDA has approved Adcertis, and it is now being sold in the market. The value of the company at the stock market is also continuing to rise, as more investors are pouring in their money because of the enormous potential of Seattle Genetics to make it big. Aside from Adcertis, Seattle Genetics also have some medicines that are now under tests to see if they can treat different kinds of cancer.

Oncotarget, Revolutionizing Healthcare Awareness through Expert Intervention

It is not a surprise that any aspect of life could be sought out without the necessity of manual efforts. This has been due to the effort of the different domains, making it easier for their products and services to have online access. Similarly, the healthcare sector is no different. An example of the technological advancements in this sector is the Oncortarget Research Journal.Oncortaget seeks to help healthcare personnel and medics to share helpful information and findings through their research journal. It is majorly focused on the deep oncology-related research. This journal was created in 2010 and then got published by impact journals having Andrei V. Gudkov and Mikhail Blagosklonny as its head editors. The Oncortarget is published weekly but this can be compromised in presence of a special request.Inspiration to come up with this medical journal was to maximize awareness of scientific findings and therefore boosting the significance of research through insightful critics.

This initiative has proven worthwhile especially because apparently the unnecessary costs due to negligence have gone down and many lives are not at stake anymore. The ultimate aim of Oncortarget is to create a disease-free world and to eradicate major deadly illnesses putting cancer in the top least.All forms of cancer have now been put to the limelight. The journal has been able to gather sufficient resources necessary for issuing therapy and treatment guidelines for cancer patients. The medics involved have come up with rare and specific strategies which would eventually improve the management of those affected by cancer.The fact that the journal’s researchers are from vast backgrounds means that whatever initiatives are put in place is of standard quality.

Being united by the same goal, a passion for sharing cancer research has been of great achievement not only to the researchers but also the healthcare sector at large.Being a free-to-all publication has steered public attention which is necessary for its growth. There have been positive responses on the brilliant setups which have played a great role in motivating the researchers who are on the potential cancer therapy case.IntegraGen, a company that is based on transforming biological samples data into genomic information has been a major part of the Oncortarget scheme. After thorough research, IntraGen released results of their recent tumor-related research through Oncortarget. This is just but one of the many significant scientific outcomes that the journal has brought to realization.

Why Oncotarget Is The Medical Journal Go To

The Oncotarget is an online journal that aims at providing insightful knowledge about the oncological area. The journal came to existence in 2010, and since then it has helped students, educators, and health specialist by being a source of knowledge. This journal ensures that scientific discoveries are distributed globally at a fast rate. It is peer reviewed by members of the scientific society. Over the years it has received positive reviews from readers.According to a member of the Oncotarget journal the journal has been helpful in helping authors increase the results of their research by providing in depth, punctual and constructive. It is also readily available to all since the site used also does not require paying of any subscription fees. The platform also contains pdf documents that one can download for future reference. The Oncotarget is a weekly journal; this simply proves that it offers recent updated on new therapies that have come into existence.

This journal has been helpful to researchers regarding science advancement. It is under the management of competent scientists who lead various medical research teams. It is through this research that medical specialists can come up with clinical studies to counter the diseases. This journal also has an impressive editorial board that conduct through editing of the work before publication. This board ensures that the articles are academically legit. Through the Oncotarget drugs have been discovered that could treat various infections. Through the information published treatments have been developed.

Some of these treatment are cancer-related treatments that have aided cancer patients improve their quality of life through better management of the disease. It has also enlightened them on other aspects related to their disease without constant attention from their care givers. It has geared the development of anti-cancer agents which have proved to be quite effective in fighting cancerous cells. Some of these include the anti-malaria drugs. The publications also include articles with reviews from patients from the treatments they have received and how it has changed their life experiences. It also contains supporting evidence to back up all the information it publishes.

Eric Lefkofsky envisions custom treatments at the molecular level

Much progress has been made in the last 50 years of cancer treatment. While the medical establishment is still a long way from a cure, one of the most productive areas of cancer treatment innovation has been in the area of what are known as targeted therapies. These drugs are able to specifically target malignant cells, using fiendishly clever bio-engineering technology, and, thus, avoid the release of toxins into the patient’s bloodstream. This class of drugs has dramatically increased the effectiveness of treatment for some types of cancers, such as non-Hodgekin’s lymphoma, and promises to all but eliminate the horrible side effects of chemotherapies used in many other types of cancer.

But now, there is another revolution in cancer treatment brewing. The marriage of Big Data with molecular biology promises to dramatically increase the effectiveness of many types of cancer treatment. This is the custom treatment revolution. Just like the targeted therapy revolution tailors drugs to attack a very narrow, specific type of cell, the custom treatment revolution promises to target a very narrow, specific type of patient. The idea is to reduce the huge amounts of collateral damage that inevitably follow from administering highly toxic treatments to large groups of undifferentiated patients.

One man, Eric Lefkofsky, is at the forefront of this new frontier in cancer research. In 2016, the serial entrepreneur founded Tempus, a company dedicated to the real-time analysis of large amounts of data for oncologists to use in custom tailoring patient treatments. Part of Tempus’ treatment model relies on the vast stores of data provided by the cheap sequencing of human genomes. This, combined with electronic medical records, study data, and other sources of medical data, will be combined with a sophisticated analytic engine, allowing for oncologists to create patient-specific treatments in real time. Eric Lefksofsky predicts that, within ten years, practically no two patients with the same cancer diagnosis will receive the same treatment. Compare that with today, where practically all patients with the same diagnosis get the same drugs in the same regimen.

This new, infinite granularity in how oncologists understand patient and treatment profiles may lead the way to a virtual cure.

About Eric Lefkofsky :